Ricardo Gazzinelli to Adjuvants, Immunologic
This is a "connection" page, showing publications Ricardo Gazzinelli has written about Adjuvants, Immunologic.
Connection Strength
0.414
-
Grimaldi G, Teva A, Porrozzi R, Pinto MA, Marchevsky RS, Rocha MG, Dutra MS, Bru?a-Romero O, Fernandes AP, Gazzinelli RT. Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS Negl Trop Dis. 2014 Jun; 8(6):e2853.
Score: 0.101
-
Junqueira C, Guerrero AT, Galv?o-Filho B, Andrade WA, Salgado AP, Cunha TM, Ropert C, Campos MA, Penido ML, Mendon?a-Previato L, Previato JO, Ritter G, Cunha FQ, Gazzinelli RT. Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One. 2012; 7(5):e36245.
Score: 0.087
-
Machado AV, Caetano BC, Barbosa RP, Salgado AP, Rabelo RH, Garcia CC, Bruna-Romero O, Escriou N, Gazzinelli RT. Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity. Vaccine. 2010 Apr 19; 28(18):3247-56.
Score: 0.075
-
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Louren?o KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025 Oct 03; 64:127756.
Score: 0.055
-
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares IS. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol?) as adjuvant. Vaccine. 2024 04 02; 42(9):2394-2406.
Score: 0.049
-
Dias Assis BR, Gomes IP, de Castro JT, Rivelli GG, de Castro NS, Gomez-Mendoza DP, Bagno FF, Hojo-Souza NS, Chaves Maia AL, Lages EB, da Fonseca FG, Ribeiro Teixeira SM, Fernandes AP, Gazzinelli RT, Castro Goulart GA. Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine. Nanomedicine (Lond). 2023 08; 18(18):1175-1194.
Score: 0.048